Anthropic in talks to buy Decart AI for $6B
Anthropic is closing in on its largest acquisition ever, and a Hong Kong-listed speech-AI firm is pushing medical imaging models further down the clinical path.
Anthropic is in talks to buy Decart AI for about $6 billion — what would be its largest acquisition yet — according to people familiar with the matter. The three-year-old Israeli startup helps AI developers squeeze more performance out of a wide range of chips and builds generative-video "world models" that can modify live video feeds in real time. Bloomberg reports the deal is not finalized and could fall through, and Anthropic declined to comment. The price tag looks steep for a startup of Decart's size, but the bidding context explains it: Calcalist reported Decart was close to a deal with Nvidia before a larger bid emerged, with SpaceX, Amazon and Nebius believed to be circling, and TechTimes put SpaceX's pursuit at a $6–7 billion valuation for faster inference.
If it closes, the deal says two things about Anthropic. First, it is willing to buy rather than rent its way to cheaper, faster compute — Decart's chip-optimization work dovetails with the in-house silicon team Anthropic confirmed earlier this month, and its video world models give Claude a foothold in a modality where it has been quiet. Second, at roughly the size of a small round for the big labs, $6 billion is a serious bet that inference efficiency, not just model quality, decides who wins the next phase of the AI race.
Unisound unveiled U2-RadiMed, which it bills as China's first full-pipeline medical imaging model — handling image understanding, report generation, clinical reasoning and visual question answering in one system. The Hong Kong-listed firm said the multimodal model accepts single or multiple images plus text, covers CXR, CT and MRI, and builds six capability blocks from lesion detection and localization to clinical decision support. The release follows the company's U2-Med model and pushes its line into radiology workflows. It is a regional product launch rather than a frontier milestone, but it shows Chinese vendors moving from general-purpose chat models toward tightly scoped clinical tools — the same specialization trend driving Western medical-AI startups.
What to watch: whether the Decart talks close and at what final price — and whether Anthropic keeps shopping ahead of its expected fall IPO.
Anthropic is reportedly paying a premium for inference speed — does buying chip expertise beat renting it? Tell us in the comments.
